| Primary |
| Bronchopulmonary Aspergillosis |
17.8% |
| Fungal Infection |
12.4% |
| Febrile Neutropenia |
7.3% |
| Pneumonia |
5.0% |
| Acanthamoeba Keratitis |
4.6% |
| Aspergillus Infection |
4.2% |
| Candida Infection |
4.2% |
| Candidiasis |
4.2% |
| Immunosuppressant Drug Therapy |
4.2% |
| Orbital Apex Syndrome |
4.2% |
| Chemotherapy |
3.9% |
| Acute Respiratory Distress Syndrome |
3.5% |
| Disseminated Intravascular Coagulation |
3.5% |
| Staphylococcal Infection |
3.5% |
| Antifungal Prophylaxis |
3.1% |
| Endophthalmitis |
3.1% |
| Infection Prophylaxis |
3.1% |
| Antibiotic Prophylaxis |
2.7% |
| Interstitial Lung Disease |
2.7% |
| Sepsis |
2.7% |
|
| Drug Ineffective |
34.4% |
| Trichosporon Infection |
7.8% |
| Platelet Count Decreased |
6.7% |
| Bronchopulmonary Aspergillosis |
5.6% |
| Systemic Mycosis |
5.6% |
| Hepatic Function Abnormal |
4.4% |
| Systemic Candida |
4.4% |
| Drug Prescribing Error |
3.3% |
| Pancreatitis Acute |
3.3% |
| Disseminated Intravascular Coagulation |
2.2% |
| Endocarditis |
2.2% |
| Eye Infection Fungal |
2.2% |
| Fungal Infection |
2.2% |
| Infection |
2.2% |
| Interstitial Lung Disease |
2.2% |
| Off Label Use |
2.2% |
| Peritoneal Effluent Abnormal |
2.2% |
| Renal Failure Acute |
2.2% |
| Renal Impairment |
2.2% |
| Rhabdomyolysis |
2.2% |
|
| Secondary |
| Drug Use For Unknown Indication |
18.5% |
| Prophylaxis |
12.4% |
| Infection Prophylaxis |
7.3% |
| Stem Cell Transplant |
7.3% |
| Pyrexia |
5.9% |
| Product Used For Unknown Indication |
5.8% |
| Fungal Infection |
5.0% |
| Neoplasm Malignant |
4.7% |
| Prophylaxis Against Graft Versus Host Disease |
4.1% |
| Infection |
4.0% |
| Febrile Neutropenia |
3.7% |
| Graft Versus Host Disease |
3.4% |
| Pneumonia |
2.8% |
| Immunosuppression |
2.6% |
| Bronchopulmonary Aspergillosis |
2.4% |
| Abdominal Pain |
2.3% |
| Aspergillus Infection |
2.2% |
| Immunosuppressant Drug Therapy |
2.1% |
| Allogenic Bone Marrow Transplantation Therapy |
1.9% |
| Sepsis |
1.7% |
|
| Drug Ineffective |
9.8% |
| White Blood Cell Count Decreased |
9.8% |
| Trichosporon Infection |
8.2% |
| Hepatic Function Abnormal |
6.6% |
| Liver Disorder |
6.6% |
| Weight Increased |
6.6% |
| Pancytopenia |
5.7% |
| Pneumonia |
5.7% |
| White Blood Cell Disorder |
4.9% |
| Zygomycosis |
4.9% |
| Urine Output Decreased |
4.1% |
| Endocarditis |
3.3% |
| Interstitial Lung Disease |
3.3% |
| Pyrexia |
3.3% |
| Renal Impairment |
3.3% |
| Systemic Mycosis |
3.3% |
| Toxic Skin Eruption |
3.3% |
| Bronchopulmonary Aspergillosis |
2.5% |
| Orbital Apex Syndrome |
2.5% |
| Renal Disorder |
2.5% |
|
| Concomitant |
| Prophylaxis |
21.5% |
| Product Used For Unknown Indication |
14.6% |
| Drug Use For Unknown Indication |
13.3% |
| Infection Prophylaxis |
5.4% |
| Multiple Myeloma |
4.5% |
| Stem Cell Transplant |
4.5% |
| Pneumonia |
4.5% |
| Immunosuppression |
3.6% |
| Neoplasm Malignant |
3.5% |
| Prophylaxis Against Graft Versus Host Disease |
3.0% |
| Infection |
2.7% |
| Pyrexia |
2.7% |
| Myelodysplastic Syndrome |
2.5% |
| Allogenic Bone Marrow Transplantation Therapy |
2.4% |
| Sedation |
2.1% |
| Fluid Replacement |
2.0% |
| Acute Myeloid Leukaemia |
1.9% |
| Febrile Neutropenia |
1.9% |
| Fungal Infection |
1.9% |
| Sepsis |
1.8% |
|
| White Blood Cell Count Decreased |
17.6% |
| Sepsis |
15.0% |
| Renal Impairment |
11.5% |
| Febrile Neutropenia |
7.2% |
| Pneumonia |
6.3% |
| Platelet Count Decreased |
5.0% |
| Pyrexia |
4.4% |
| Respiratory Failure |
3.5% |
| Thrombocytopenia |
3.3% |
| Septic Shock |
3.1% |
| Renal Failure Acute |
2.6% |
| White Blood Cell Count Increased |
2.6% |
| Venoocclusive Liver Disease |
2.4% |
| Vomiting |
2.4% |
| Diarrhoea |
2.2% |
| Hepatic Function Abnormal |
2.2% |
| Interstitial Lung Disease |
2.2% |
| Pulmonary Alveolar Haemorrhage |
2.2% |
| Renal Failure |
2.2% |
| Shock |
2.2% |
|
| Interacting |
| Dermatomyositis |
33.3% |
| Antifungal Prophylaxis |
16.7% |
| Cytomegalovirus Infection |
16.7% |
| Fungal Infection |
16.7% |
| Pneumocystis Jiroveci Pneumonia |
8.3% |
| Pneumocystis Jirovecii Pneumonia |
8.3% |
|
| Respiratory Failure |
100.0% |
|
